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Low vitaminD is involved in allergic asthma and rhinitis. IL-31 and IL-33 correlate withTh2-associated cytokines in allergic disease.
We investigated whether low vitamin D is linked with circulating IL-31 and IL-33 in children with allergic disease of the airways.
25-Hydroxyvitamin D [25(OH) Vit D], IL-31, and IL-33 plasma levels were measured in 28 controls (HC), 11 allergic rhinitis (AR)
patients, and 35 allergic asthma with rhinitis (AAR) patients. We found significant lower levels of 25(OH) Vit D in AR and in AAR
than in HC. IL-31 and IL-33 plasma levels significantly increased in AAR than HC. IL-31 and IL-33 positively correlated in AR
and AAR. 25(OH) Vit D deficient AAR had higher levels of blood eosinophils, exacerbations, disease duration, and total IgE than
patients with insufficient or sufficient 25(OH) Vit D. In AAR 25(OH) Vit D levels inversely correlated with total allergen sIgE score
and total atopy index. IL-31 and IL-33 did not correlate with 25(OH) Vit D in AR and AAR. In conclusion, low levels of 25(OH)
Vit D might represent a risk factor for the development of concomitant asthma and rhinitis in children with allergic disease of the
airways independently of IL-31/IL-33 Th2 activity.
1. Introduction
The hormonal form of vitamin D affects both adaptive and
innate immune functions involved in the development of
allergies [1]. Genetic factors of the vitamin D metabolism are
involved in the development of allergic conditions showing
a direct association between vitamin D receptor polymor-
phisms and atopic asthma [2]. Furthermore, studies on an
animalmodel provided evidence for a link between early vita-
min D supplementation and the later allergy where several
vitamin D regulated genes seem to be involved [3]. Recently,
low serum vitamin D levels were observed in association
with airway obstruction and corticosteroid requirement in
asthmatic patients influencing the asthma severity, atopy, or
both [4–6].
Vitamin D in the form of 1,25-dihydroxyvitamin D is a
potent immune system modulator and at the molecular level
has been shown to be involved in the suppression of dendritic
cell maturation and consecutive Th1 cell development [7–
9]. In fact, vitamin D may suppress the production of IL-
12, thereby reducing the production of T helper type 1 (Th1)
cells and potentially leading to increased proliferation of
allergy-associated T helper type 2 (Th2) cells [7]. Addition-
ally, studies in mice have shown that treatment with 1,25-
dihydroxyvitamin D results in the reduced secretion of Th1-
type cytokines IL-2 and IFN-𝛾 and an increase in Th2-type
IL-4 [10].
Interleukin 33 (IL-33) potently drives the production of
proinflammatory Th2-associated cytokines, including IL-4,
IL-5, and IL-13, by in vitro polarized Th2 cells [11], mast
cells [12], basophils and eosinophils [13, 14], and dendritic
cells [15]. Furthermore, hematopoietic cells produce other
inflammatory cytokines and chemokines, including IL-6 and
IL-8, via IL-33 stimulation [14]. These activities suggest
potential roles for IL-33 inTh2-associated immune responses,
and thus IL-33 is thought to be closely associated with allergic
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inflammatory diseases, including asthma. Indeed, increased
IL-33 levels were observed in the bronchoalveolar lavage
fluid from subjects with moderate asthma compared with
mild asthmatics and controls without asthma [16]. A single-
nucleotide polymorphism in IL-33 that showed a suggestive
association with the circulating eosinophil count was also
significantly associated with atopic asthma [17].
Interleukin 31 (IL-31) is a T helper type 2 effector cytokine
that plays an important role in the pathogenesis of atopic
and allergic diseases. IL-31, mainly produced by activated
Th2 cells, interacts with a heterodimeric receptor consisting
of IL-31 receptor A (IL-31RA) and the oncostatin M recep-
tor (OSMR) constitutively expressed on epithelial cells and
keratinocytes. Plasma IL-31 concentration was found to be
significantly elevated in patients with atopic dermatitis (AD)
compared to healthy individuals [18] and positively correlated
with disease severity [19].Mainly, a crucial immunopatholog-
ical role of IL-31 and IL-33 was observed in AD suggesting
their inflammatory effect in atopic disease [20].
The present study aims to investigate the plasma levels
of 25(OH) Vit D, IL-31, and IL-33 in children with allergic
asthma and rhinitis. Furthermore, since lower levels of
25(OH)Vit D and high levels of IL-31 and IL-33 are associated
with Th2 immunity of allergic disease, we hypothesized a
potential interaction between these markers and clinical and
functional parameters in asthma and rhinitis.
2. Methods
2.1. Subjects. Pediatric subjects (age between 8 and 13 years)
were recruited among outpatients attending the Pulmonol-
ogy/Allergy Clinic of the National Research Council of Italy
in Palermo. Asthma diagnosis and assessment of severity
were performed according to Global Initiative for Asthma
(GINA) guidelines [21]. AR diagnosis was performed at the
study entry according to Allergic Rhinitis and its Impact on
Asthma (ARIA) guidelines [22].
The patients were divided in two groups: 35 children
had concomitant intermittent to persistent allergic rhinitis
and intermittent to moderate allergic asthma (AAR), and 11
patients had intermittent to persistent allergic rhinitis (AR).
The control group, having negative assessment of the atopic
status and no asthma or rhinitis symptoms, was composed of
28 healthy children (HC). Children stopped the treatment for
asthma (ICS) or rhinitis (antihistamines or topical steroid) 1
month before entering in the study.
No patients had nasal polyposis or bronchial or respira-
tory tract infections or had a severe exacerbation of asthma
resulting in hospitalization during the last month. Within 2
days from blood samples, all subjects performed pulmonary
function tests as recommended by the GINA guidelines.
The study was approved by the Ethics Committee of
the University Hospitals of Palermo and complied with the
Helsinki Declaration (N∘7/2013). Written informed consent
was obtained from the parents of the patients enrolled in the
study.
2.2. Assessment of the Atopic Status. Skin prick tests were
performed according to EAACI recommendations [23] with
a standard panel includingDermatophagoidesmix, grass mix,
Parietaria judaica, olive, dog and cat dander, Alternaria,
and Blattella germanica, plus a positive (histamine 1%) and
a negative (saline) control (Stallergenes Italia S.r.l., Milan,
Italy).The readingwas performed after 15min: reactionswere
considered positive if themean wheal diameter (computed as
the maximum diameter plus its orthogonal divided by two)
was 3mm or greater, after having subtracted the wheal diam-
eter of the reaction to the negative control. Total and allergen-
specific serum IgE levels were determined by CAP System
(Pharmacia-Upjohn,Uppsala, Sweden).The total atopy index
(degree of allergic sensitization) was also assessed, which
is defined as the total number of allergens tested to which
each subject had a positive response [24]. The total allergen
sIgE score (sum of classes of allergen specific IgE test) was
considered as a quantitative score able to reflect the levels of
allergen exposure and the degree of multiple sensitizations in
the patients [25]. Total eosinophil count was performed using
standard procedures.
2.3. Measurement of Plasma 25(OH) Vit D by ELISA. Plas-
ma 25(OH) Vit D was assayed using an enzyme linked im-
munosorbent assay (ELISA) kit (Immunodiagnostic System
Ltd., Boldon Business Park, Boldon, Tyne and Wear, UK)
according to the manufacturer instructions. The absorbance
was read at 450 nm (reference 620 nm) by a Wallac 1420 Vic-
tor2 multilabel counter (Perkin-Elmer Life Sciences, Turku,
Finland). This method had 100% and 75% specificity for
25(OH)D3 and 25(OH)D2, respectively, and assessed the
overall vitaminD status but did not distinguish between these
two forms [26]. The limit of detection was 2 ng/mL. The
intra- and interassay coefficients of variation were 5.3% and
4.6%, respectively. Samples were run in duplicate with quality
control samples to ensure day-to-day validity of results.
2.4. Measurements of Plasma IL-31 and IL-33 by ELISA.
Plasma IL-31 and IL-33 protein levels were measured using
the commercially available DuoSet ELISA Development Sys-
tem kits (R &D Systems;Minneapolis, MN, USA) specific for
human IL-31 and human IL-33. All analyses were performed
according to the manufacturer’s protocol. Absorbance was
measured at 450 nm (correctionwavelength set at 540 nm) by
a Wallac 1420 Victor2 multilabel counter (Perkin-Elmer Life
Sciences, Turku, Finland).The detection limit was 15.6 pg/mL
for IL-31 and 4.0 pg/mL for IL-33.
2.5. Statistical Analysis. Statistical analysis was performed
using Kruskal-Wallis test and the differences between groups
were evaluated by nonparametric Mann-Whitney U test.
Correlation analyses were performed with Spearman’s rank
test. The chi-square (𝜒2) analysis was performed to evaluate
differences in frequency distributions of variables. Data were
expressed as means ±SD or median values with interquartile
ranges. A 𝑃 value < 0.05 was considered statistically signifi-
cant.
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Table 1: Demographic, clinical, and atopic characteristic of the subjects.
Control (HC) Allergicrhinitis (AR)
Allergic asthma
rhinitis
(AAR)
Overall 𝑃 value
Age, (years)
range
10.6 (±2.2)
8–12
10.3 (±2.1)
8–11
10.7 (±2.5)
9–13 ns
Sex, 𝑛 (male/female) 28 (17/11) 11 (8/3) 35 (22/13) ns
Body mass index, (kg/m2)
range
25.1 (±10.3)
17.8–32.3
18.6 (±4.8)
14.8–19.7
19.6 (±3.0)
17.1–21.3 ns
FEV1 (% predicted) 110.0 (±9.0) 107.7 (±16.7) 93.5 (±12.6) <0.0001
FVC (% predicted) 95.5 (±19) 106 (±118) 92.9 (±12.1) <0.0001
PEF (% predicted) 80.6 (±14.6) 79.7 (±18.6) 60.1 (±15.7) <0.0001
SPT, any positive, 𝑛 (%) 0 100 100 <0.0001
Total IgE (IU/mL), (geometric mean)
log tot IgE
39.7
1.60 (±0.21)
293.2
2.47 (±0.47)
320.5
2.51 (±0.41)
<0.0001
<0.0001
Total allergen sIgE score 0 6.0 (±3.3) 6.7 (±4.7) <0.0001
Rast to dust mites 0 2.4 (±2.0) 2.1 (±2.0) <0.0001
Exacerbations (last year) 0 NA 2.1 (±1.5) <0.0001
Disease duration (yrs) 0 4.2 (±2.0) 5.6 (±2.5) <0.0001
Data are presented as mean ± standard deviation unless otherwise stated. FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PEF = peak
expiratory flow; SPT = skin prick test. Statistical analysis for multiple comparisons was calculated by Kruskal-Wallis test.
3. Results
3.1. Demographic Characteristics of Patients. We reported the
demographic, clinical, and atopic characteristics of all pa-
tients included in the study in Table 1.
3.2. 25(OH) Vit D, IL-31, and IL-33 in Patients with AR and
AAR. We found significant lower levels of 25(OH) Vit D in
AR (median; range: 24.0 ng/mL, 22.5–28.3; 𝑃 < 0.01) and in
AAR (median; range: 23.5 ng/mL, 21.0–27.1; 𝑃 = 0.0003) than
in HC (median; range: 35.0 ng/mL, 26.3–46.0) (Figure 1(a)).
IL-31 and IL-33 levels increased in AAR and AR than in
HC (Figures 1(b) and 1(c)); the difference was statistically
significant only between AAR and HC (IL-31: 𝑃 < 0.03; IL-
33: 𝑃 < 0.005) although higher levels of IL-31 and IL-33 were
observed in AR than in HC (Figures 1(b) and 1(c)).
In accordance with 25(OH) Vit D levels, we categorized
subjects of each group enclosed in the study as deficient
(def: <20 ng/mL), insufficient (insuff: ≥20 and <30 ng/mL),
and sufficient (suff: ≥30 ng/mL) as previously described [27].
Frequency distribution of 25(OH) Vit D status classes (defi-
ciency, insufficiency, and sufficiency) in HC, AR, and AAR
groups is shown in Table 2. Differences in the distribution are
significant (𝑃 < 0.009(𝜒2)).
3.3. Correlation between 25(OH) Vit D, IL-31, and IL-33 in
Patients with AR and AAR. In AR and AAR patients, no
correlation was found between the 25(OH) Vit D levels and
IL-31 or IL-33 levels (data not shown). However, IL-31 and IL-
33 plasma levels showed a positive correlation in AR (𝑃 <
0.003) (Figure 2(a)) and in AAR patients (𝑃 < 0.0001)
(Figure 2(b)).
3.4. 25(OH) Vit D Level, IL-31, IL-33, and Atopic Status in
Patients with Allergic Diseases. We analyzed plasma levels of
IL-31 and IL-33 in AR and AAR patients grouped by 25(OH)
Vit D status. IL-31 and IL-33 were not significantly different
in AR and AAR patients showing deficient, insufficient, or
sufficient 25(OH)VitD levels.However, IL-31 and IL-33 levels
were higher in AAR patients with insufficient or sufficient
25(OH) Vit D (Figure 3). Additionally, we analyzed clinical
and atopic parameters in AR and AAR patients grouped by
25(OH) Vit D status. We observed in AAR, but not in AR
group, that patients with deficient 25(OH) Vit D had higher
levels of blood eosinophils (number/mm3), exacerbations
(number/last year), disease duration (yrs), and total IgE
(IU/mL) than patients with insufficient or sufficient 25(OH)
Vit D without significant differences among the groups
(Figure 4). Again, only in AAR group, 25(OH) Vit D levels
inversely correlated with total allergen sIgE score (sum of
classes of allergen specific IgE test) (𝑃 < 0.008) (Figure 5(a))
and patients with deficient or insufficient 25(OH) Vit D
showed significant higher levels of total allergen sIgE score
than those with sufficient 25(OH)Vit D (Figure 5(b)). Finally,
in AAR group, 25(OH) Vit D levels inversely correlated
with total atopy index (number of positive allergens) (𝑃 <
0.03) (Figure 6(a)) and patients with deficient 25(OH) Vit
D showed significant higher levels of total atopy index
than patients with insufficient or sufficient 25(OH) Vit D
(Figure 6(b)). This finding clearly suggests that low levels
of 25(OH) Vit D are associated with the degree of multiple
allergen sensitizations only in patients with AAR.
AAR pediatric patients, showing positive sIgE to dust
mites, had significant lower 25(OH) Vit D levels than chil-
dren negative to dust mites sIgE (𝑃 < 0.02). The median
concentrations of 25(OH) Vit D levels were 22.1 ng/mL
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Figure 1: Plasma levels of 25(OH) Vit D (ng/mL), IL-31 (pg/mL), and IL-33 (pg/mL) in HC (𝑛 = 28) compared to patients with AR (𝑛 = 11)
and patients with AAR (𝑛 = 35). 25(OH) Vit D concentrations (a), IL-31 concentrations (b), and IL-33 concentrations (c) were analyzed by
specific ELISA. Bars in the box plots indicate (from the bottom to the top) 10th, 25th, 50th (median), 75th, and 90th percentiles. Statistical
analysis was performed by Kruskal-Wallis test and Mann-Whitney U test. Significance was accepted at 𝑃 < 0.05.
Table 2: Frequency distribution of vitamin D status classes among HC, AR, and AAR groups.
HC
𝑛 = 28
AR
𝑛 = 11
AAR
𝑛 = 35
𝑃 value
(𝜒2)
Vitamin D status <0.009
Deficient (<20 ng/mL), 𝑛 (%) 1 (3.6%) 2 (18.2%) 6 (17.1%)
Insufficient (20–30 ng/mL), 𝑛 (%) 10 (35.7%) 7 (63.6%) 22 (62.9%)
Sufficient (>30 ng/mL), 𝑛 (%) 17 (60.7%) 2 (18.2%) 7 (20.0%)
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Figure 2: Correlation between plasma IL-31 and IL-33 concentrations in (a) AR patients (𝑛 = 11) and (b) AAR patients (𝑛 = 35). Statistical
analysis was performed by Spearman rank test. Significance was accepted at 𝑃 < 0.05.
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Figure 3: IL-31 and IL-33 plasma levels and 25(OH) Vit D status in patients with AAR (𝑛 = 35). (a) IL-31 concentrations and (b) IL-33
concentrations were measured by specific ELISA in AAR patients with deficient (𝑛 = 6), insufficient (𝑛 = 22), or sufficient (𝑛 = 7) 25(OH)
Vit D levels. Bars represent mean ±SD. Statistical analysis was performed by Kruskal-Wallis test. Significance was accepted at 𝑃 < 0.05.
(range: 19.1–24.1) in dust mite positive AAR children and
25.94 ng/mL (range: 24.9–31.1) in dust mite negative AAR
children (Figure 7). The same differences were not observed
in AR patients. No associations between positive sIgE levels
to cat, dog, Alternaria species, tree mix, grass mix, and weed
mix and 25(OH) Vit D levels were found (data not shown) in
AAR and AR children.
4. Discussion
The present study investigated for the first time the relation-
ship between IL-31, IL-33, and 25(OH) Vit D in pediatric
allergic disease of the airways. We observed that although all
these markers appear to be involved in allergic rhinitis and
in concomitant allergic asthma and rhinitis, no correlations
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Figure 4: Asthma control parameters and 25(OH) Vit D status in patients with AAR (𝑛 = 35). (a) Blood eosinophils (number/mm3), (b)
exacerbations (number/last year), (c) disease duration (yrs), and (d) total IgE (IU/mL) in AAR patients with deficient (𝑛 = 6), insufficient
(𝑛 = 22), or sufficient (𝑛 = 7) 25(OH) Vit D levels. Bars in the box plots indicate (from the bottom to the top) 10th, 25th, 50th (median), 75th,
and 90th percentiles. Statistical analysis was performed by Kruskal-Wallis test. Significance was accepted at 𝑃 < 0.05.
were observed between 25(OH) Vit D and IL-31 or IL-33.
These results suggest that lower levels of 25(OH) Vit D
affect allergic disease of the airways independently of the
pathological role of IL-31 and IL-33. Finally, we observed
that children with concomitant asthma and rhinitis, show-
ing deficient 25(OH) Vit D, have higher levels of blood
eosinophils, exacerbations in last year, disease duration, total
allergen sIgE score, and total atopy index. These findings
might underline that low levels of 25(OH) Vit D represent a
major favorable outcome for children with allergic rhinitis to
develop concomitant allergic asthma.
The knowledge on direct mechanistic links between
vitamin D and lung diseases are limited. However, a number
of epidemiological and experimental available data highlight
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the relevance of this connection [28]. Vitamin D has complex
effects on pulmonary cell biology and immunity with impact
on inflammation, host defense, wound healing, repair, and
other processes modulating the function of various immune
cells. Interestingly, vitamin D may protect from developing
respiratory infections that could serve as trigger for a deterio-
ration of asthma [29] and is potentially capable of overcoming
the poor glucocorticoid responsiveness in severe asthmatics
by upregulation of IL-10 production from CD4+ T cells [30].
Accordingly, showing 25(OH) Vit D lower levels in children
with AR and AAR, we underline that a lack of 25(OH) Vit
D levels is able to increase the risk of allergic disease of the
airways in children. However, the underlying mechanisms by
which vitamin D modulates the pathogenesis of asthma are
not clear and further studies might be necessary to clarify its
involvement in the immunology of airway disease.
CD4+ T cells producing Th2-type cytokines are thought
to have a pivotal role in orchestrating the recruitment and
activation of these effector cells of the allergic response [31].
IL-31 is a cytokine produced by CD4+ T cells playing an
important role in allergic inflammation often showing a
potent immunological link with IL-33 [32]. IL-31 receptor IL-
31RA, oncostatin M receptor, and IL-33 receptor ST2/IL1RL1
are also related with the immunopathological mechanisms
of allergic diseases [33–35]. IL-33 exerts its function through
the ST2 receptor, a critical component of Th2 response
[36], generating the production of IL-31 [33]. IL-31 signals
act through a receptor composed of IL-31 receptor A and
oncostatin M receptor promoting the cell activation during
allergic diseases [35]. Accordingly, we observed statistically
significant higher levels of IL-31 and IL-33 in children with
AAR than in HC and, though without a statistical difference,
in AR than in HC. In both AR and AAR the levels of IL-
31 and IL-33 positively correlated. These findings underline
that IL-31 and IL-33 are linked and might be involved in the
pathogenesis of allergic rhinitis and asthma with a potential
role in the progression of allergic disease in asthma. In this
scenario, we are able to hypothesize that IL-31 and the related
IL-33 activity might be linked with vitamin D in allergic
disease. Nevertheless, we observed that the levels of IL-31 and
IL-33 were not statistically different in patients with AAR and
ARwith deficient, insufficient, and sufficient levels of 25(OH)
Vit D. Indeed the fact that we even observed higher levels of
IL-31 and IL-33 in patients with AAR showing insufficient
and sufficient 25(OH) Vit D levels further underlined the
lack of relationship between 25(OH) Vit D IL-31 and IL-33 in
allergic disease. VitaminD is able tomodulate the function of
CD4+ T cells particularly reversing the defective induction of
IL-10-secreting regulatory T cells in glucocorticoid-resistant
asthma patients [30]. Nevertheless, our results suggest that
it is not involved in IL-33/IL-31 Th2-type cytokines activity
implicated in bronchial and nasal allergic disease. Finally,
in accordance with our results, it was observed that serum
IL-31 is related to oncostatin M and vitamin D3 levels in
normal donors, while no correlation with vitamin D was
observed in patients with AD [35]. In this scenario we can
speculate that our results might underline that IL-31 and the
related IL-33 are not Th2 cytokines in the classical sense as
previously described [32]. Particularly, we suggest that since
IL-31 is likely to be expressed by a number of cells in the
allergic situations in which IL-4 is present and promotesTh2-
driven inflammation [36], it contributes in allergic reaction
involving the vitamin D deficiency only partially. However
further studies might be necessary to clarify the mechanism
how vitamin D is able to control the activity of CD4+ T cells
and the related Th2-type cytokines in the pathogenesis of
allergic disease.
Vitamin D deficiency has been blamed as one cause
of increased asthma prevalence in the last decades [37].
Epidemiologic studies have also shown thatmaternal vitamin
D intake during pregnancy protects from wheezing in child-
hood [38]. A recent clinical investigation showed that high
vitamin D levels are associated with better lung function, less
airway hyperresponsiveness, and improved glucocorticoid
response [39]. VitaminD deficiency/insufficiency is common
in children with mild to moderate persistent asthma and
is associated with higher odds of severe exacerbation [40].
Accordingly, we showed that children with concomitant
allergic rhinitis and asthma, having deficient or insufficient
25(OH) Vit D, had marked characteristic of disease in terms
of exacerbationnumber in the last year and in terms of disease
duration (yrs). Our findings support the concept that the
intake of lower levels of vitamin D in asthmatic children
is able to influence a worse course of the allergic disease,
representing a minor favorable outcome for children with
allergic rhinitis to develop concomitant asthma.
There is little knowledge about clinical variables asso-
ciated with vitamin D deficiency/insufficiency in asthmatic
children, with numerous controversies in the literature
regarding the role of vitamin D in allergy. One hypothesis
for the increasing prevalence of asthma involves vitamin D.
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Some have argued that vitamin D has more of a deleterious
effect on allergic pathogenesis [3]. Although multiple studies
have examined maternal vitamin D status and subsequent
wheezing in offspring [41], there are limited data on vitamin
D levels in children with asthma, as well as on which
features of asthma are associated with vitamin D levels.
However, a recent large epidemiological study looking at
data from a British cohort showed an association between
elevated IgE levels and very low (<25 nmol/L) or very high
25-hydroxyvitamin D3 (>135 nmol/L) levels. Nevertheless, a
significant but nonlinear relationship was found between 25-
hydroxyvitamin D3 status and IgE levels. It therefore appears
that too little or too much vitamin D may predispose to
the development of allergic immune responses [42]. In this
scenario, despite the controversy in the literature and despite
our small sample of children with concomitant allergic
asthma and rhinitis, we showed that the levels of 25(OH) Vit
D inversely correlated with total allergy sIgE score and with
total atopy index, further demonstrating a negative effect of
lower levels of vitaminD on respiratory allergic diseases.This
finding clearly suggests that low levels of 25(OH) Vit D are
associated to the degree of multiple allergen sensitizations in
the patients. Finally, we showed that children with AAR with
positive sIgE to dust mites had lower levels of 25(OH) Vit D.
These findings further underline and support the concept that
vitamin D might be necessary as an adjunct to subcutaneous
allergen immunotherapy in asthmatic children sensitized to
house dust mite as previously described [43].
In conclusion, this study demonstrated the effect of
vitamin D levels on the related outcomes of asthma and
of allergic phenotypes of the disease, with a particular link
with the host dust mite sensitization. Since most allergies
start in childhood, vitamin D deficiency or insufficiency
in childhood might influence initiation of allergy targeting
unclear and little known immunologic aspect of the disease.
Further clinical studiesmight clarify the link between vitamin
D and asthma and allergic immunologic features.
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